This PubMed entry describes a systematic review and meta-analysis titled "Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis." The piece is indexed with PMID 41979328 and is available in full text on PubMed Central (PMCID PMC13449447). The article was published in Blood Advances on 11 August 2026 (10[15]:5293–5307) and carries DOI 10.1182/bloodadvances.2025019530.
The review examines the diagnostic roles of two laboratory modalities commonly used in the workup of suspected systemic light-chain (AL) amyloidosis: immunofixation and the serum free light chain (FLC) assay.
The manuscript is authored by Muayad Azzam and a large, multi-institutional team. Authors represent academic centers and specialty services across North America and internationally, including departments of internal medicine, hematology, cardiology, nephrology, pathology, and oncology. Specific institutional affiliations listed in the PubMed record include The University of Kansas Medical Center, Saint Louis University, Mayo Clinic, Tufts Medical Center, Boston University Medical Center, Princess Margaret Cancer Centre, and other academic and clinical centers.
PubMed classifies the work as a Meta-Analysis. Bibliographic details available in the record include publication date (2026 Aug 11), journal (Blood Advances), volume and issue (10[15]), page range (5293–5307), DOI, PMID, and PMCID. The PubMed entry links to full-text options including the free PMC article.
According to the title and PubMed indexing, the review focuses on evaluating the diagnostic utility—that is, the performance characteristics relevant to identifying monoclonal free light chains or clonal immunoglobulin—of immunofixation electrophoresis and serum free light chain assays specifically in the setting of AL amyloidosis. These tests are central to detecting an underlying plasma cell dyscrasia that drives AL amyloid deposition.
The PubMed record does not include the detailed abstract content or pooled diagnostic estimates in the excerpt provided here. Therefore, the specific outcomes synthesized by the meta-analysis—such as pooled sensitivity, specificity, positive and negative predictive values, likelihood ratios, or diagnostic odds ratios—are not available in the supplied source text.
The PubMed entry indicates that the full article is accessible via PubMed Central (PMCID PMC13449447). All standard bibliographic identifiers appear in the record (PMID, PMCID, DOI), facilitating retrieval of the complete methods, inclusion criteria, data extraction approach, statistical analyses, and pooled diagnostic accuracy results.
The provided PubMed excerpt supplies comprehensive bibliographic metadata (title, author list, affiliations, journal, publication date, DOI, PMID, PMCID) and classification as a meta-analysis. However, the excerpt does not include:
Because these critical items are absent from the supplied source text, no quantitative performance measures or evidence-based recommendations can be restated here without consulting the full article.
Clinicians and laboratory directors seeking evidence on the diagnostic accuracy of immunofixation and serum FLC assay in suspected AL amyloidosis should retrieve and read the full meta-analysis (PMCID PMC13449447) to review the pooled estimates, study selection, and limitations before incorporating the findings into diagnostic workflows.
Key items to evaluate in the full text include the number and types of included studies, pooled sensitivity and specificity (with confidence intervals), how monoclonal protein detection was defined across studies, performance in different specimen types (serum versus urine), the handling of renal impairment (which affects FLC values), and the authors' discussion of clinical applicability and limitations.
Until those details are examined directly from the article, no definite statements about the diagnostic accuracy or recommended testing algorithm can be made from the PubMed record alone.
The PubMed record documents a comprehensive, multi-author systematic review and meta-analysis addressing the diagnostic utility of immunofixation and free light chain assay in AL amyloidosis, published in Blood Advances in August 2026. Full methodological and result data are not present in the provided excerpt; clinicians should consult the PMC full text (PMCID PMC13449447) for the numerical diagnostic performance metrics and the authors' conclusions before applying the findings clinically.